From: Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
Authors
patients n=
Number of PRRT cycles
Median Follow-Up [months]
CR/PR/MRa
SDb
PDc
This study
35
5–8
25
1 (3.1)
26 (81.6)
5 (15.3)
Sabet et al. [12]
33
23
7 (21.2)
14 (42.4)
11 (33.3)
van der Zwan et al. [14]
168
30.4
26 (15.5)
100 (59.5)
33 (19.6)